Abstract
AIM: To study cerebrospinal fluid (CSF) activity of tissue plasminogen activator (tPA) in patients with neurological diseases. METHODS: CSF tPA and urokinase (uPA) activities were studied using an immunocapture assay and zymography in 44 patients with neurological disease and 20 reference subjects. The patient group comprised three patients with meningitis, 21 with encephalitis, nine with acute lymphoblastic (n = 7) and myeloid (n = 2) leukaemia, seven with multiple sclerosis, three with facial paresis, and one with polyradiculitis. RESULTS: Raised tPA activities were observed in patients with multiple sclerosis, leukaemia and encephalitis. In contrast, there were no differences in the mean activities of tPA in patients with meningitis or other diseases compared with the reference subjects. The highest tPA activities were found in patients with multiple sclerosis. The mean activity in patients with leukaemia was higher than in those with meningitis and polyradiculitis, but not encephalitis and facial paresis. Although the CSF tPA activity correlated positively with age in reference subjects, no correlation was observed in patients. Samples were qualitatively screened for both tPA and uPA activity by zymography and positive samples were quantitated. Some of the samples had quantifiable levels of uPA activity: three of seven multiple sclerosis samples, 10 of 21 samples from patients with encephalitis and five of nine leukaemic samples. The highest activities were recorded in patients with leukaemia. uPA was not detected in the CSF of the patients with meningitis, facial paresis or polyradiculitis. CONCLUSIONS: Plasminogen activator activity can be measured reliably in CSF and the assessment of tPA activity may be useful for studying the pathogenesis of neurological diseases.
Full text
PDF![577](https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ebf9/500574/e23cc5294dd3/jclinpath00244-0053.png)
![578](https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ebf9/500574/e40688b0de0b/jclinpath00244-0054.png)
![579](https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ebf9/500574/213b3c684485/jclinpath00244-0055.png)
![580](https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ebf9/500574/689119c4f6fc/jclinpath00244-0056.png)
Selected References
These references are in PubMed. This may not be the complete list of references from this article.
- Almér L. O., Sundkvist G., Lilja B. Fibrinolytic activity, autonomic neuropathy, and circulation in diabetes mellitus. Diabetes. 1983 May;32 (Suppl 2):4–7. doi: 10.2337/diab.32.2.s4. [DOI] [PubMed] [Google Scholar]
- Bartens W., Wanner C. Lipoprotein(a): new insights into an atherogenic lipoprotein. Clin Investig. 1994 Aug;72(8):558–567. doi: 10.1007/BF00227446. [DOI] [PubMed] [Google Scholar]
- Bizik J., Stephens R. W., Grofova M., Vaheri A. Binding of tissue-type plasminogen activator to human melanoma cells. J Cell Biochem. 1993 Mar;51(3):326–335. doi: 10.1002/jcb.240510312. [DOI] [PubMed] [Google Scholar]
- Carroll P. M., Tsirka S. E., Richards W. G., Frohman M. A., Strickland S. The mouse tissue plasminogen activator gene 5' flanking region directs appropriate expression in development and a seizure-enhanced response in the CNS. Development. 1994 Nov;120(11):3173–3183. doi: 10.1242/dev.120.11.3173. [DOI] [PubMed] [Google Scholar]
- Chapman M. J., Huby T., Nigon F., Thillet J. Lipoprotein (a): implication in atherothrombosis. Atherosclerosis. 1994 Oct;110 (Suppl):S69–S75. doi: 10.1016/0021-9150(94)05385-v. [DOI] [PubMed] [Google Scholar]
- Danø K., Andreasen P. A., Grøndahl-Hansen J., Kristensen P., Nielsen L. S., Skriver L. Plasminogen activators, tissue degradation, and cancer. Adv Cancer Res. 1985;44:139–266. doi: 10.1016/s0065-230x(08)60028-7. [DOI] [PubMed] [Google Scholar]
- De Vries T. J., Mooy C. M., Van Balken M. R., Luyten G. P., Quax P. H., Verspaget H. W., Weidle U. H., Ruiter D. J., Van Muijen G. N. Components of the plasminogen activation system in uveal melanoma--a clinico-pathological study. J Pathol. 1995 Jan;175(1):59–67. doi: 10.1002/path.1711750110. [DOI] [PubMed] [Google Scholar]
- Deutsch D. G., Mertz E. T. Plasminogen: purification from human plasma by affinity chromatography. Science. 1970 Dec 4;170(3962):1095–1096. doi: 10.1126/science.170.3962.1095. [DOI] [PubMed] [Google Scholar]
- Dore-Duffy P., Donovan C., Todd R. F., 3rd Expression of monocyte activation antigen Mo3 on the surface of peripheral blood monocytes from patients with multiple sclerosis. Neurology. 1992 Aug;42(8):1609–1614. doi: 10.1212/wnl.42.8.1609. [DOI] [PubMed] [Google Scholar]
- Dore-Duffy P., Washington R., Dragovic L. Expression of endothelial cell activation antigens in microvessels from patients with multiple sclerosis. Adv Exp Med Biol. 1993;331:243–248. doi: 10.1007/978-1-4615-2920-0_38. [DOI] [PubMed] [Google Scholar]
- Friedman G. C., Seeds N. W. Tissue plasminogen activator expression in the embryonic nervous system. Brain Res Dev Brain Res. 1994 Aug 12;81(1):41–49. doi: 10.1016/0165-3806(94)90066-3. [DOI] [PubMed] [Google Scholar]
- García Frade L. J., Sureda A., Torrado M. C., García Avello A. High plasma urokinase-type plasminogen activator levels are present in patients with acute nonlymphoblastic leukemia. Acta Haematol. 1992;88(1):7–10. doi: 10.1159/000204586. [DOI] [PubMed] [Google Scholar]
- García-Rocha M., Avila J., Armas-Portela R. Tissue-type plasminogen activator (tPA) is the main plasminogen activator associated with isolated rat nerve growth cones. Neurosci Lett. 1994 Oct 24;180(2):123–126. doi: 10.1016/0304-3940(94)90502-9. [DOI] [PubMed] [Google Scholar]
- Geiger M., Binder B. R. Plasminogen activation in diabetes mellitus. Kinetic analysis of plasmin formation using components isolated from the plasma of diabetic donors. J Biol Chem. 1984 Mar 10;259(5):2976–2981. [PubMed] [Google Scholar]
- Gijtenbeek J. M., Emeis J. J., van der Sande J. J., Lulf R. E. Different types of plasminogen activator activity in human brain tumours: relation with peritumoral oedema? Clin Neurol Neurosurg. 1994 Nov;96(4):305–309. doi: 10.1016/0303-8467(94)90119-8. [DOI] [PubMed] [Google Scholar]
- Green G. D., Shaw E. Thiobenzyl benzyloxycarbonyl-L-lysinate, substrate for a sensitive colorimetric assay for trypsin-like enzymes. Anal Biochem. 1979 Mar;93(2):223–226. doi: 10.1016/s0003-2697(79)80141-4. [DOI] [PubMed] [Google Scholar]
- Inman R. D., Harpel P. C. Alpha 2-plasmin inhibitor-plasmin complexes in synovial fluid. J Rheumatol. 1986 Jun;13(3):535–537. [PubMed] [Google Scholar]
- Koskiniemi M., Vaheri A., Taskinen E. Cerebrospinal fluid alterations in herpes simplex virus encephalitis. Rev Infect Dis. 1984 Sep-Oct;6(5):608–618. doi: 10.1093/clinids/6.5.608. [DOI] [PubMed] [Google Scholar]
- Laemmli U. K. Cleavage of structural proteins during the assembly of the head of bacteriophage T4. Nature. 1970 Aug 15;227(5259):680–685. doi: 10.1038/227680a0. [DOI] [PubMed] [Google Scholar]
- Norton W. T., Brosnan C. F., Cammer W., Goldmuntz E. A. Mechanisms and suppression of inflammatory demyelination. Acta Neurobiol Exp (Wars) 1990;50(4-5):225–235. [PubMed] [Google Scholar]
- Rao J. S., Chen M., Festoff B. W. Plasminogen activator inhibitor 1, the primary regulator of fibrinolysis, in normal human cerebrospinal fluid. J Neurosci Res. 1993 Feb 15;34(3):340–345. doi: 10.1002/jnr.490340311. [DOI] [PubMed] [Google Scholar]
- Ridker P. M., Hennekens C. H., Stampfer M. J., Manson J. E., Vaughan D. E. Prospective study of endogenous tissue plasminogen activator and risk of stroke. Lancet. 1994 Apr 16;343(8903):940–943. doi: 10.1016/s0140-6736(94)90064-7. [DOI] [PubMed] [Google Scholar]
- Ridker P. M., Vaughan D. E., Stampfer M. J., Manson J. E., Hennekens C. H. Endogenous tissue-type plasminogen activator and risk of myocardial infarction. Lancet. 1993 May 8;341(8854):1165–1168. doi: 10.1016/0140-6736(93)90998-v. [DOI] [PubMed] [Google Scholar]
- Romanic A. M., Madri J. A. Extracellular matrix-degrading proteinases in the nervous system. Brain Pathol. 1994 Apr;4(2):145–156. doi: 10.1111/j.1750-3639.1994.tb00825.x. [DOI] [PubMed] [Google Scholar]
- Sawaya R., Rayford A., Kono S., Ang K. K., Feng Y., Stephens L. C., Rao J. S. Plasminogen activator inhibitor-1 in the pathogenesis of delayed radiation damage in rat spinal cord in vivo. J Neurosurg. 1994 Sep;81(3):381–387. doi: 10.3171/jns.1994.81.3.0381. [DOI] [PubMed] [Google Scholar]
- Short C. D., Durrington P. N., Mallick N. P., Bhatnagar D., Hunt L. P., MBewu A. Serum lipoprotein (a) in men with proteinuria due to idiopathic membranous nephropathy. Nephrol Dial Transplant. 1992;7 (Suppl 1):109–113. [PubMed] [Google Scholar]
- Stephens R. W., Tapiovaara H., Reisberg T., Bizik J., Vaheri A. Alpha 2-macroglobulin restricts plasminogen activation to the surface of RC2A leukemia cells. Cell Regul. 1991 Dec;2(12):1057–1065. doi: 10.1091/mbc.2.12.1057. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Stephens R., Alitalo R., Tapiovaara H., Vaheri A. Production of an active urokinase by leukemia cells: a novel distinction from cell lines of solid tumors. Leuk Res. 1988;12(5):419–422. doi: 10.1016/0145-2126(88)90061-6. [DOI] [PubMed] [Google Scholar]
- Stephens R., Leung K. C., Pöllänen J., Salonen E. M., Vaheri A. Microplate immunocapture assay for plasminogen activators and their specific inhibitors. J Immunol Methods. 1987 Dec 24;105(2):245–251. doi: 10.1016/0022-1759(87)90272-9. [DOI] [PubMed] [Google Scholar]
- Sugita K., Suzuki N., Shimizu N., Takanashi J., Ishii M., Niimi N. Involvement of cytokines in N-methyl-N'-nitro-N-nitrosoguanidine-induced plasminogen activator activity in acute disseminated encephalomyelitis and multiple sclerosis lymphocytes. Eur Neurol. 1993;33(5):358–362. doi: 10.1159/000116971. [DOI] [PubMed] [Google Scholar]
- Sutton R., Keohane M. E., VanderBerg S. R., Gonias S. L. Plasminogen activator inhibitor-1 in the cerebrospinal fluid as an index of neurological disease. Blood Coagul Fibrinolysis. 1994 Apr;5(2):167–171. doi: 10.1097/00001721-199404000-00002. [DOI] [PubMed] [Google Scholar]
- Tapiovaara H., Alitalo R., Stephens R., Myöhänen H., Ruutu T., Vaheri A. Abundant urokinase activity on the surface of mononuclear cells from blood and bone marrow of acute leukemia patients. Blood. 1993 Aug 1;82(3):914–919. [PubMed] [Google Scholar]
- Washington R., Burton J., Todd R. F., 3rd, Newman W., Dragovic L., Dore-Duffy P. Expression of immunologically relevant endothelial cell activation antigens on isolated central nervous system microvessels from patients with multiple sclerosis. Ann Neurol. 1994 Jan;35(1):89–97. doi: 10.1002/ana.410350114. [DOI] [PubMed] [Google Scholar]
- Wilson E. L., Jacobs P., Dowdle E. B. The secretion of plasminogen activators by human myeloid leukemic cells in vitro. Blood. 1983 Mar;61(3):568–574. [PubMed] [Google Scholar]